Table 1 ATT use and treatment failure
From: What does IGRA testing add to the diagnosis of ocular tuberculosis? A Bayesian latent class analysis
ATT given | ATT and tx failure | No ATT and tx failure | |
|---|---|---|---|
Male | 61.7% (87/141) | 16.1% (14/87) | 29.6% (16/54) |
Female | 34.1% (43/126) | 34.9% (15/43) | 36.1% (30/83) |
Asian | 50.4% (71/141) | 23.9% (17/71) | 31.4% (22/70) |
African | 49.1% (27/55) | 18.5% (5/27) | 50.0% (14/28) |
Caucasian | 45.1% (32/71) | 21.9% (7/32) | 25.6% (10/39) |
Oral steroids | 60.7% (91/150) | 26.4% (24/91) | 50.8% (30/59) |
No oral steroids | 33.3% (39/117) | 12.8% (5/39) | 20.5% (16/78) |
No choroidal involvement | 48.5% (113/233) | 22.1% (25/113) | 32.5% (39/120) |
Choroidal involvement | 50.0% (17/34) | 23.5% (4/17) | 41.2% (7/17) |
Anterior uveitis | 44.9% (22/49) | 22.7% (5/22) | 33.3% (9/27) |
Intermediate uveitis | 44.6% (29/65) | 24.1% (7/29) | 27.8% (10/36) |
Posterior uveitis | 52.6% (50/95) | 20.0% (10/50) | 51.1% (23/45) |
Posterior uveitis with choroidal involvement | 47.4% (9/19) | 11.1% (1/9) | 60.0% (6/10) |
Unilateral involvement | 50.5% (53/105) | 18.9% (10/53) | 34.6% (18/52) |
Bilateral involvement | 47.5% (77/162) | 24.7% (19/77) | 32.9% (28/85) |
QFT ≤ 0.35 | 46.1% (35/76) | 31.4% (11/35) | 24.4% (10/41) |
QFT 0.35–2.00 | 47.4% (27/57) | 25.9% (7/27) | 43.3% (13/30) |
QFT > 2.00 | 50.7% (68/134) | 16.2% (11/68) | 34.8% (23/66) |
All patients | 48.7% (130/267) | 22.3% (29/130) | 33.6% (46/137) |